Drug Trial Radar · NCT06675175
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Dec 9, 2024
Primary completion
Oct 27, 2025
Study completion Oct 27, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
Conditions
- Chronic Kidney Disease
- Atherosclerotic Cardiovascular Disease
Interventions
AZD4144Drug
Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.
PlaceboOther
Placebo will be given orally to randomized participants as per the arm they are assigned.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: From first dose (Day 1) until Follow-up (Day 56±1)
- Relative change from baseline to 4 weeks in systemic Interleukin-6 (IL-6) levelsTime frame: Day 1 to Day 28
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Glendale, California
Research Site
Daytona Beach, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Port Orange, Florida
Research Site
Tampa, Florida
Research Site
Farmington Hills, Michigan
Research Site
The Bronx, New York
Research Site
Sherman, Texas
Research Site
Pleven, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Gyöngyös, Hungary
Research Site
Kistarcsa, Hungary
Research Site
Bucharest, Romania
Research Site
Cluj-Napoca, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.